Entera's Oral Osteoporosis Drug Shows Stronger Bone Gains in High-Risk Patients, Phase 3 Design Unveiled
ENTX has more than doubled off its 52-week low of $0.91 on light trading volume (0.2× avg).
Summary
Entera Bio presented new post-hoc Phase 2 data at ASBMR 2026 showing EB613, its oral PTH(1-34) tablet, produced markedly greater bone mineral density gains in postmenopausal women with osteoporosis (T-score ≤-2.5) than in those with osteopenia. In the high-risk subgroup, placebo-adjusted BMD increases at 6 months were 4.23% at total hip and 4.22% at lumbar spine, versus 1.02% and 1.59% in the lower-risk group. The company also detailed its registrational Phase 3 design: approximately 900 patients randomized 2:1 to EB613 or placebo, with 12-month total hip BMD change as the primary endpoint. This follows the July $275M private placement that extended cash runway to 2030 and removed the going concern warning. The data support the Phase 3 population selection and de-risk the program's path toward registration.
At the time of this announcement, ENTX was trading at $2.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $460.7M. The 52-week trading range was $0.91 to $4.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.